David Kolstad
Chief Executive Officer, President
New England Cell Therapeutics (NECTx) was founded in 2019 to deliver next-generation cell therapies to patients suffering from a broad range of injuries and illnesses.
NECTx’s work leverages a proprietary cell technology platform called Stemirac® that was developed in Japan and has rapidly progressed to a conditional approval by the PMDA. NECTx’s Japanese parent company, Nipro Corporation, has invested significantly in establishing extensive, world-class cell processing capabilities that serve as the backbone of NECTx’s developmental work in the U.S.
It is NECTx’s initial mission to bring its differentiated cell therapy approach to patients in the United States who have been diagnosed with Amyotrophic Lateral Sclerosis (ALS).
Chief Executive Officer, President
Chief Medical Officer, Head of Regulatory Affairs
Chief Financial Officer